AKEBIA THERAPEUTICS, INC. Net Income (Loss) Available to Common Stockholders, Diluted
AKEBIA THERAPEUTICS, INC. (AKBA) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$20.04 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2024-11-07
- AKEBIA THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2024-09-30 was -$20.04M.
- AKEBIA THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2024-06-30 was -$8.58M.
- AKEBIA THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2024-03-31 was -$17.98M.
- AKEBIA THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2023-09-30 was -$14.49M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month as first filed |
|---|---|---|---|---|---|---|
| 2024-09-30 | -$20.04M 10-Q · filed 2024-11-07 | -$28.62M derived: sum of 2 quarters · filed 2024-11-07 | -$46.61M 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | -$8.58M 10-Q · filed 2024-08-08 | -$26.57M 10-Q · filed 2024-08-08 | ||||
| 2024-03-31 | -$17.98M 10-Q · filed 2024-05-09 | |||||
| 2023-09-30 | -$14.49M 10-Q · filed 2024-11-07 | -$25.66M derived: sum of 2 quarters · filed 2024-11-07 | -$52.54M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | -$11.17M 10-Q · filed 2024-08-08 | -$38.05M 10-Q · filed 2024-08-08 | ||||
| 2023-03-31 | -$26.88M 10-Q · filed 2024-05-09 | -$26.22M 10-Q · filed 2023-05-08 | ||||
| 2022-09-30 | -$54.10M 10-Q · filed 2023-11-08 | -$51.87M 10-Q · filed 2022-11-03 | -$24.65M derived: sum of 2 quarters · filed 2023-11-08 | -$88.16M 10-Q · filed 2023-11-08 | -$85.01M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $29.45M 10-Q · filed 2023-08-28 | $29.28M 10-Q · filed 2022-08-04 | -$34.06M 10-Q · filed 2023-08-28 | -$33.15M 10-Q · filed 2022-08-04 | ||
| 2022-03-31 | -$63.51M 10-Q · filed 2023-08-28 | -$62.42M 10-Q · filed 2023-05-08 | ||||
| 2021-09-30 | -$59.54M 10-Q · filed 2022-11-03 | -$142.58M derived: sum of 2 quarters · filed 2022-11-03 | -$212.16M 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | -$83.04M 10-Q · filed 2022-08-04 | -$152.62M 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |